| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cistanoside A reduces NO accumulation but shows no effect on iNOS mRNA, iNOS protein levels, or iNOS enzymatic activity. Its anti-inflammatory mechanism may involve direct scavenging of NO or modulation of upstream inflammatory signals.
|
|---|---|
| ln Vitro |
In vitro, Cistanoside A reduces NO accumulation in activated macrophages or other inflammatory cells. It has also shown protective activities against CCl4-induced hepatotoxicity.
|
| ln Vivo |
In vivo, Cistanoside A possesses protective activities against CCl4-induced hepatotoxicity in mice, which is associated with increasing free radical scavenging activities, alleviating lipid peroxidation, and improving mitochondrial respiratory chain function.
|
| Enzyme Assay |
NO accumulation is measured using the Griess reagent in cell culture supernatants. iNOS mRNA, protein, and activity are assessed by qPCR, Western blotting, and enzymatic assays, respectively.
|
| Cell Assay |
Macrophages (e.g., RAW264.7) are cultured and stimulated with LPS to induce iNOS expression and NO production. Cistanoside A is added to the culture, and NO levels in the supernatant are measured.
|
| Animal Protocol |
CCl4-induced hepatotoxicity models in mice are used. Cistanoside A is administered orally or intraperitoneally, and liver enzyme levels, oxidative stress markers, and mitochondrial function are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not extensively characterized. As a glycoside, it is expected to undergo deglycosylation and metabolism. Oral bioavailability may be limited.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Phenylethanoid glycosides are generally considered to have a low toxicity profile. No significant adverse effects have been reported at research doses.
|
| References | |
| Additional Infomation |
It has been reported that Cistanche salsa and Cistanche deserticola contain [(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(4-hydroxy-3-methoxyphenyl)ethoxy]-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxacyclohexane-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxacyclohexane-2-yl]oxacyclohexane-3-yl](E)-3-(3,4-dihydroxyphenyl)acrylate. See also: Cistanche glycoside A (note moved to).
Cistanoside A is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of anti-inflammatory and hepatoprotective activities. |
| Molecular Formula |
C36H48O20
|
|---|---|
| Molecular Weight |
800.75
|
| Exact Mass |
800.273
|
| CAS # |
93236-42-1
|
| PubChem CID |
101691130
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
1058.1±65.0 °C at 760 mmHg
|
| Flash Point |
324.2±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.676
|
| LogP |
2.46
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
56
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)OC)O)O)O)O
|
| InChi Key |
LOGNFAUMIGACHZ-WEDRDYHSSA-N
|
| InChi Code |
InChI=1S/C36H48O20/c1-15-25(42)27(44)30(47)36(52-15)56-33-31(48)35(50-10-9-17-4-7-19(39)21(12-17)49-2)54-23(14-51-34-29(46)28(45)26(43)22(13-37)53-34)32(33)55-24(41)8-5-16-3-6-18(38)20(40)11-16/h3-8,11-12,15,22-23,25-40,42-48H,9-10,13-14H2,1-2H3/b8-5+/t15-,22+,23+,25-,26+,27+,28-,29+,30+,31+,32+,33+,34+,35+,36-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(4-hydroxy-3-methoxyphenyl)ethoxy]-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~124.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2488 mL | 6.2441 mL | 12.4883 mL | |
| 5 mM | 0.2498 mL | 1.2488 mL | 2.4977 mL | |
| 10 mM | 0.1249 mL | 0.6244 mL | 1.2488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
